United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright

United Therapeutics (NASDAQ:UTHR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $425.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 32.83% from the stock’s current price.

Several other equities research analysts have also commented on the company. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Trading Down 1.1 %

United Therapeutics stock opened at $319.96 on Thursday. The firm has a market capitalization of $14.28 billion, a P/E ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.57. The stock has a fifty day moving average price of $359.65 and a 200 day moving average price of $360.46. United Therapeutics has a 52 week low of $221.53 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the firm posted $4.36 earnings per share. As a group, equities analysts predict that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,164 shares of company stock valued at $45,278,893. Insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Milestone Asset Management LLC lifted its holdings in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 1,037 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after buying an additional 789 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares during the last quarter. Franklin Resources Inc. lifted its holdings in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares during the last quarter. Finally, Burney Co. lifted its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after buying an additional 12,705 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.